A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

NCT06905873 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Vitiligo

Interventions

DRUG: FB102
DRUG: Placebo

Sponsor

Forte Biosciences, Inc.